Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1991 1
1992 1
1995 1
2001 1
2005 2
2006 3
2007 1
2008 1
2009 3
2010 2
2011 1
2012 3
2013 7
2014 2
2015 4
2016 4
2017 9
2018 7
2019 7
2020 5
2021 7
2022 9
2023 5
2024 4
2025 4
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Among authors: brittain c. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.
Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, Lai TYY, Haskova Z, Sakamoto T, Kotecha A, Schlottmann PG, Liu Y, Seres A, Retiere AC, Willis JR, Yoon YH; BALATON and COMINO Investigators. Tadayoni R, et al. Among authors: brittain c. Ophthalmology. 2024 Aug;131(8):950-960. doi: 10.1016/j.ophtha.2024.01.029. Epub 2024 Jan 26. Ophthalmology. 2024. PMID: 38280653 Free article. Clinical Trial.
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C; all Archway Investigators. Holekamp NM, et al. Among authors: brittain c. Ophthalmology. 2022 Mar;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016. Epub 2021 Sep 29. Ophthalmology. 2022. PMID: 34597713 Free article. Clinical Trial.
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, Haier B, Jimenez T, Brittain C, Liu J, Barbey C, Stach C. Furie RA, et al. Among authors: brittain c. Rheumatology (Oxford). 2021 Nov 3;60(11):5397-5407. doi: 10.1093/rheumatology/keab381. Rheumatology (Oxford). 2021. PMID: 33956056 Free PMC article. Clinical Trial.
'My patient died'.
Brittain C. Brittain C. Nursing. 2019 Apr;49(4):50-51. doi: 10.1097/01.NURSE.0000553276.26343.5f. Nursing. 2019. PMID: 30893205
Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial.
Pieramici DJ, Awh CC, Chang M, Emanuelli A, Holekamp NM, Hu AY, Suñer IJ, Wykoff CC, Brittain C, Howard D, Quezada-Ruiz C, Santhanakrishnan A, Latkany P. Pieramici DJ, et al. Among authors: brittain c. JAMA Ophthalmol. 2025 Apr 1;143(4):317-325. doi: 10.1001/jamaophthalmol.2025.0001. JAMA Ophthalmol. 2025. PMID: 40048178 Free PMC article. Clinical Trial.
Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase III SatraGO-1 and SatraGO-2 Randomized Trials.
Briceño CA, Idowu OO, Khong JJ, Kuenzel T, Tran AQ, Brittain C, Azumi A, Brockwell L, Ghadiri N, Coronel M, Ruf T, Li D, Salvi M, Garrido-Hermosilla AM, Barteselli G, Ortiz-Perez S; SatraGO-1 and SatraGO-2 investigators. Briceño CA, et al. Among authors: brittain c. Ophthalmology. 2026 Sep 7:S0161-6420(26)00673-1. doi: 10.1016/j.ophtha.2026.08.039. Online ahead of print. Ophthalmology. 2026. PMID: 42705581 Free article.
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial.
Bähner F, Faust SN, Davies LRL, Blokhina O, Brandon DM, Smith WB, Chatterjee VKK, Hassanin H, Babu TM, Zuiani A, Steinhauser S, Poran A, Brittain C, Mucker E, Hooper JW, van der Most RG, Alonso PL, Türeci Ö, Mensa FJ, Şahin U. Bähner F, et al. Among authors: brittain c. Lancet Infect Dis. 2026 Oct;26(10):1045-1057. doi: 10.1016/S1473-3099(26)00177-5. Epub 2026 Jun 3. Lancet Infect Dis. 2026. PMID: 42235570 Clinical Trial.
88 results